INTRODUCTION: Droperidol is a controversial drug with multiple clinical applications. This report examines the use of droperidol in pediatric emergency department (ED) patients. METHODS: An observational structured chart review was conducted of patients 21 years or younger receiving droperidol as part of their ED treatment. RESULTS: Over a 32-month period, 79 ED records were identified for review. Patients' ages ranged from 15 to 21 years with a mean age of 19.4 (T0.2) years. Indications for droperidol included agitation, 68 (86%); nausea/vomiting, 7 (9%); headache, 2 (3%); and other pain, 2 (3%). Droperidol was the initial therapy in 63 patients (80%) and the rescue medication in 16 (20%). In nonagitated patients, droperidol was 100% effective in controlling patient's symptoms, whereas in agitated patients, droperidol alone was 86.6% effective as a single agent. Within the agitated patients, 35 (51.5%) were positive for drugs, 15 (22.1%) were positive for drugs and alcohol, and 12 (17.6%) were positive for alcohol alone. All patients were placed on continuous cardiac monitoring immediately after administration of the drug and for the duration of their active ED visit. No cardiac arrhythmias were noted. Thirty-eight patients (48%) were discharged from the ED, 35 (44%) were transferred to the psychiatric crisis unit for evaluation, 5 (6%) were admitted, and in 1 patient with biliary colic, the disposition was not recorded. No admissions were for droperidol-associated complications. CONCLUSIONS: Droperidol is a safe and effective medication in the adolescent and young adult population.
INTRODUCTION:Droperidol is a controversial drug with multiple clinical applications. This report examines the use of droperidol in pediatric emergency department (ED) patients. METHODS: An observational structured chart review was conducted of patients 21 years or younger receiving droperidol as part of their ED treatment. RESULTS: Over a 32-month period, 79 ED records were identified for review. Patients' ages ranged from 15 to 21 years with a mean age of 19.4 (T0.2) years. Indications for droperidol included agitation, 68 (86%); nausea/vomiting, 7 (9%); headache, 2 (3%); and other pain, 2 (3%). Droperidol was the initial therapy in 63 patients (80%) and the rescue medication in 16 (20%). In nonagitated patients, droperidol was 100% effective in controlling patient's symptoms, whereas in agitated patients, droperidol alone was 86.6% effective as a single agent. Within the agitated patients, 35 (51.5%) were positive for drugs, 15 (22.1%) were positive for drugs and alcohol, and 12 (17.6%) were positive for alcohol alone. All patients were placed on continuous cardiac monitoring immediately after administration of the drug and for the duration of their active ED visit. No cardiac arrhythmias were noted. Thirty-eight patients (48%) were discharged from the ED, 35 (44%) were transferred to the psychiatric crisis unit for evaluation, 5 (6%) were admitted, and in 1 patient with biliary colic, the disposition was not recorded. No admissions were for droperidol-associated complications. CONCLUSIONS:Droperidol is a safe and effective medication in the adolescent and young adult population.
Authors: John P Scott; Eckehard A E Stuth; Astrid G Stucke; Joseph R Cava; Richard J Berens Journal: Pediatr Cardiol Date: 2014-08-03 Impact factor: 1.655
Authors: Luis Hernández-Rodríguez; Fernanda Bellolio; Daniel Cabrera; Alicia E Mattson; Derek VanMeter; Andrew E Grush; Lucas Oliveira J E Silva Journal: Am J Emerg Med Date: 2021-12-22 Impact factor: 2.469